These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 28059468

  • 1. Gene expression analysis combined with functional genomics approach identifies ITIH5 as tumor suppressor gene in cervical carcinogenesis.
    Dittmann J, Ziegfeld A, Jansen L, Gajda M, Kloten V, Dahl E, Runnebaum IB, Dürst M, Backsch C.
    Mol Carcinog; 2017 Jun; 56(6):1578-1589. PubMed ID: 28059468
    [Abstract] [Full Text] [Related]

  • 2. ITIH5 mediates epigenetic reprogramming of breast cancer cells.
    Rose M, Kloten V, Noetzel E, Gola L, Ehling J, Heide T, Meurer SK, Gaiko-Shcherbak A, Sechi AS, Huth S, Weiskirchen R, Klaas O, Antonopoulos W, Lin Q, Wagner W, Veeck J, Gremse F, Steitz J, Knüchel R, Dahl E.
    Mol Cancer; 2017 Feb 23; 16(1):44. PubMed ID: 28231808
    [Abstract] [Full Text] [Related]

  • 3. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
    Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E.
    Oncogene; 2008 Jan 31; 27(6):865-76. PubMed ID: 17653090
    [Abstract] [Full Text] [Related]

  • 4. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia.
    Steenbergen RD, Kramer D, Braakhuis BJ, Stern PL, Verheijen RH, Meijer CJ, Snijders PJ.
    J Natl Cancer Inst; 2004 Feb 18; 96(4):294-305. PubMed ID: 14970278
    [Abstract] [Full Text] [Related]

  • 5. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
    Rose M, Gaisa NT, Antony P, Fiedler D, Heidenreich A, Otto W, Denzinger S, Bertz S, Hartmann A, Karl A, Knüchel R, Dahl E.
    Carcinogenesis; 2014 Mar 18; 35(3):727-36. PubMed ID: 24265292
    [Abstract] [Full Text] [Related]

  • 6. ITIH5 shows tumor suppressive properties in cervical cancer cells grown as multicellular tumor spheroids.
    Daum AK, Dittmann J, Jansen L, Peters S, Dahmen U, Heger JI, Hoppe-Seyler F, Gille A, Clement JH, Runnebaum IB, Dürst M, Backsch C.
    Am J Transl Res; 2021 Mar 18; 13(9):10298-10314. PubMed ID: 34650698
    [Abstract] [Full Text] [Related]

  • 7. Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype.
    Kloten V, Rose M, Kaspar S, von Stillfried S, Knüchel R, Dahl E.
    Epigenetics; 2014 Sep 18; 9(9):1290-301. PubMed ID: 25093535
    [Abstract] [Full Text] [Related]

  • 8. ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.
    Rose M, Meurer SK, Kloten V, Weiskirchen R, Denecke B, Antonopoulos W, Deckert M, Knüchel R, Dahl E.
    Mol Carcinog; 2018 Feb 18; 57(2):167-181. PubMed ID: 28940371
    [Abstract] [Full Text] [Related]

  • 9. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
    Dötsch MM, Kloten V, Schlensog M, Heide T, Braunschweig T, Veeck J, Petersen I, Knüchel R, Dahl E.
    Epigenetics; 2015 Feb 18; 10(10):903-12. PubMed ID: 26252352
    [Abstract] [Full Text] [Related]

  • 10. Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer.
    Sasaki K, Kurahara H, Young ED, Natsugoe S, Ijichi A, Iwakuma T, Welch DR.
    Clin Exp Metastasis; 2017 Apr 18; 34(3-4):229-239. PubMed ID: 28289921
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Promoter hypermethylation of SOX11 promotes the progression of cervical cancer in vitro and in vivo.
    Li X, Wu X, Li Y, Cui Y, Tian R, Singh N, Ding M, Yang Y, Gao Y.
    Oncol Rep; 2019 Apr 18; 41(4):2351-2360. PubMed ID: 30720133
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis.
    Overmeer RM, Henken FE, Bierkens M, Wilting SM, Timmerman I, Meijer CJ, Snijders PJ, Steenbergen RD.
    J Pathol; 2009 Nov 18; 219(3):327-36. PubMed ID: 19662663
    [Abstract] [Full Text] [Related]

  • 15. Aberrant Hypermethylation of SALL3 with HPV Involvement Contributes to the Carcinogenesis of Cervical Cancer.
    Wei X, Zhang S, Cao D, Zhao M, Zhang Q, Zhao J, Yang T, Pei M, Wang L, Li Y, Yang X.
    PLoS One; 2015 Nov 18; 10(12):e0145700. PubMed ID: 26697877
    [Abstract] [Full Text] [Related]

  • 16. Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis.
    Yang WT, Zheng PS.
    PLoS One; 2014 Nov 18; 9(2):e88827. PubMed ID: 24551169
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
    Rose M, Noetzel E, Kistermann J, Eschenbruch J, Rushrush S, Gan L, Knüchel R, Gaisa NT, Dahl E.
    Cells; 2021 Apr 28; 10(5):. PubMed ID: 33924987
    [Abstract] [Full Text] [Related]

  • 20. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.
    Lando M, Fjeldbo CS, Wilting SM, C Snoek B, Aarnes EK, Forsberg MF, Kristensen GB, Steenbergen RD, Lyng H.
    Epigenetics; 2015 Apr 28; 10(10):970-80. PubMed ID: 26291246
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.